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ttention-Deficit/Hyperactivity Disorder 
(ADHD) is the most common 
neurobehavioral disorder of 
childhood with an estimated 
prevalence of 7.2% worldwide1 
and 13% in Iowa.2 ADHD is diagnosed clinically 
based on the presence of a persistent pattern 
of inattention and/or hyperactivity/impulsivity 
presenting before 12 years of age with 
symptoms in two or more settings for at least 
six months that is inconsistent with 
developmental level and interferes with social, 
academic, or occupational functioning, and 
symptoms are not better explained by a 
mental health disorder (mood disorder, anxiety 
disorder, personality disorder, or substance 
intoxication). The American Academy of 
Pediatrics (AAP) revised the clinical practice 
guidelines3 with key points summarized below. 
By Shirley K. Johnson, MSN, ARNP, CPNP, Pediatric Nurse 
Practitioner and Shruti Tewar, MBBS, MPH, Clinical Assistant 
Professor, Division of Developmental and Behavioral Pediatrics, 






• Primary Care Clinicians (PCCs) should 
evaluate for ADHD in any child or 
adolescent (4 years to 18th birthday) who 
presents with behavior problems and 
symptoms of inattention, hyperactivity,  
or impulsivity.
• Diagnosis should involve thorough history 
using DSM-5 criteria, information gathering 
from multiple sources (parents, teachers/
daycare, or other clinicians) and observation 
of child’s behavior.
• DSM-based ADHD rating scales are not 
diagnostic, but should be used to support 
the evaluation.
• Two-thirds of children with ADHD have a 
coexisting emotional, behavioral, learning, 
ADHD
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or mental health condition. Children, especially 
adolescents, should be screened for coexisting 
conditions (anxiety, depression, learning difficulties, 
ODD, conduct disorder, substance abuse, and sleep 
difficulties). This information can impact management 
of ADHD.
Screening tools 
Collect from observers in at least two settings (parents 
and school teachers).
• Preschool age – ADHD Rating Scale IV Preschool 
Version and/or Conners Comprehensive Behavior 
Rating Scale
• School age – Vanderbilt Assessment Scale 
When appropriately scored, interpreted, and 
documented, these can be billed with code 96127.
Special considerations 
For preschoolers with concern for ADHD, evidence- 
based Parent Training in Behavior Management (PTBM)  
is recommended before giving a diagnosis. Parent  
Child Interaction Therapy (PCIT) and Positive Parenting 
Programs (Triple P) are examples of PTBM. Play therapy  
is not effective and has not shown improvement  
in behavior management due to lack of a parent  
training component.
For adolescents, information from at least two teachers 
should be obtained. Adolescents should be actively 
involved in their evaluation.
Psychology testing is not necessary for diagnosis,  
but is recommended for evaluation of learning or 
cognitive concerns identified during assessment.
Management
ADHD is a chronic disorder and PCCs should follow 
principles of the Chronic Care Model and medical home.
Behavioral therapy
• For preschoolers with ADHD, PCCs should prescribe 
PTBM and/or behavioral classroom interventions as 
first-line treatment.  
• Behavioral parent and classroom training should 
prevent and respond to behaviors targeting 
interrupting, aggression, task completion, and 
compliance with directions.
• Therapy in adolescents should target skill 
development and improving executive function skills.
School supports
• Children and adolescents with ADHD may be eligible 
for services at school as part of the 504 Rehabilitation 
Act plan (504 plan) or an Individualized Education  
Plan (IEP) under the Individuals with Disabilities 
Education Act (IDEA). 
• Strong family and school partnership  
is recommended.
• PCCs should advocate for behavioral support in  
school even if the child’s/adolescent’s ADHD 
symptoms are well managed on medication. 
• In Iowa, the Family & Educator Partnership (FEP) 
provides an opportunity for parents and educators to 
build partnerships to improve educational programs 
for children with special needs and has a designated 
Family & Educator Coordinator for each Area 
Education Agency.
Medications 
• The goal of medication is to reduce impairment in 
daily life due to ADHD symptoms.
• Cardiovascular screening should be done prior to 
starting medications. If the screening is negative,  
an EKG is not necessary prior to starting stimulants.
• For school-aged children, the PCC should prescribe 
FDA-approved medications for ADHD with PTBM, and/
or classroom interventions and behavioral supports.
• For preschoolers, methylphenidate, although not 
FDA approved, may be considered when behavioral 
interventions alone are not sufficient. 
• There is strong evidence for stimulants, but not as 
strong for atomoxetine, extended-release guanfacine, 
and extended-release clonidine.
• Choice of medication is dependent on efficacy of 
agent, desired duration of coverage, whether a child 
can swallow pills or capsules, out-of-pocket costs,  
and insurance coverage.
• Generally, methylphenidate or amphetamine groups 
of drugs are recommended as first-line agents and are 
FDA approved for children ≥6 years. Both groups of 
drugs have similar desired and adverse effects.
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• If other family members have tolerated a medication 
from a specific group, it can be trialed first. 
• Short-acting medications generally last for four  
hours and extended-release preparations avoid the 
need for school-based administration of medication, 
with fewer daily doses and improved compliance.
• Stimulant medications are fast acting, so efficacy  
can be determined and the dose adjusted weekly  
until optimum drug/dose is achieved.
• ADHD rating scales should be completed regularly 
by parents and teachers to guide medication 
management and dose adjustment.
• A child may need trial of two or more medications 
before a good fit is found. Parental counseling is 
important at the onset of a medication trial. 
• Non-stimulant medications can be used as an adjunct 
if appropriate symptom control is not achieved on 
stimulants alone, significant side effects are noted on 
stimulant medication, there is concern for diversion/
abuse, or caregiver preference. 
• A follow-up visit is recommended four weeks after 
starting the medication and monthly until optimum 
response is obtained. After that, visits should occur 
every three months in the first year of treatment. 
Subsequently, if symptom control is stable, face-to-
face visits are recommended quarterly or at least  
every six months for medication management.
• Additional medication management may be  
needed for coexisting sleep difficulties, or mental 
health conditions. More specific algorithms on 
medication management can be found in Guideline 
for the Assessment and Treatment of Children 
and Adolescents with Complex Attention-Deficit/
Hyperactivity Disorder.4
• Pharmacogenetic testing is not recommended at  
this time due to lack of evidence about utility.
Evaluation and Management  
of Autism Spectrum Disorders
Shruti Tewar, MBBS, MPH, Clinical Assistant Professor, 
Division of Developmental and Behavioral Pediatrics, 
University of Iowa Stead Family Children’s Hospital
Autism Spectrum Disorder (ASD) is a neurodevelopmental 
disorder with deficits in social-emotional communication/
interaction and restricted, repetitive patterns of behavior. 
In the U.S., prevalence is estimated to be 1:54 children 
(1.85%)5 with predominance in boys (4.3:1). DSM-5 
criteria for diagnosis of ASD stipulate an individual must 
demonstrate deficits in all three areas of social-emotional 
communication/interactions (social-emotional 
reciprocity; nonverbal communicative behaviors during 
social interactions; and developing, maintaining, and 
understanding relationships) and have two of the four 
symptoms of restricted, repetitive patterns of behavior:
• Stereotyped or repetitive motor movements,  
use of objects, or speech;
• Insistence of sameness or inflexible adherence  
of routines; 
• Highly restricted, fixated interests that are  
abnormal in intensity or focus; 
Management of Common Side 
Effects of Stimulant Medication
Appetite suppression – Heavy, high-calorie  
meals before taking medication and in the 
evening. Give daily bedtime snack. Monitor 
growth at every visit. If the child falls below 
two growth curves, discontinue medication.
Sleep difficulties – Strong emphasis on 
good sleep hygiene. No screen time one  
hour before bedtime. Melatonin OTC can be trialed 
1-5 mg. If not effective, can trial clonidine or 
trazodone at bedtime. 
Irritability/mood changes – Discontinue  
medication and trial a different medication from 
same or different group. The first medication  
can be trialed again when the child is older.
Rebound hyperactivity/irritability in evening – 
Consider small dose of short-acting stimulant to  
be given no later than 4 p.m. Dosing later may 
interfere with sleep onset and appetite at dinner 
time. Consider using a non-stimulant in the  
evening if ADHD is impairing evening routines.
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• Hypo-reactivity or hyperreactivity to sensory  
input or unusual interests in sensory aspects  
of the environment. 
In addition, these symptoms are not otherwise  
explained by developmental delays or underlying  
mental health conditions, such as anxiety disorders, 
ADHD, and seizure disorders. Approximately 30% of 
children with ASD will also have intellectual disability. 
Psychiatric conditions (ADHD, anxiety disorders, mood 
disorders, OCD, or others) have been identified in  
70-90% of children and youth with ASD. The AAP  
recently published updated guidelines6 on evaluation  
and management of ASD discussed in this article.
Red flags and screening
Developmental surveillance should be done at all visits by 
screening for parental concerns about child development 
or learning. Red flags prompting further screening are: 
EARLY SYMPTOMS OF ASD
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Screening tools
• Ages 16-30 months: M-CHAT-R/F™
• Ages 4 and up:  Social Communication  
Questionnaire (SCQ)
Autism screening tools can be billed with code 96110  
with an E/M code. 
Referral and resources
• Formal hearing and vision should be tested in  
the primary care setting to rule out impairments 
affecting social communication.
• Children < 3 years should be referred to early 
intervention services also known as Early ACCESS.
• Children > 3 years should be referred to their  
regional Area Education Agency (AEA) to determine 
services in the school setting. Children with ASD  
are eligible to participate in special education 
preschool, even if they are not toilet trained.  
• Children with concerns for developmental delay 
in speech or fine motor/gross motor skills should 
be referred for private therapy (speech therapy, 
occupational, and/or physical therapy) without  
waiting for a diagnostic evaluation for autism.
• Lastly, children should be referred for diagnostic 
assessment with a qualified health care professional 
and further recommendations. 
Diagnosis
A comprehensive evaluation by a trained specialist is 
needed, but a primary care clinician (PCC) trained and 
comfortable with applying DSM-5 criteria can make the 
initial clinical diagnosis. Diagnosis involves observation of 
symptoms with detailed developmental history, and use 
of validated, structured observation tools such as Autism 
Diagnostic Observation Schedule, 2nd Edition (ADOS-2)  
or Childhood Autism Rating Scale, 2nd Edition (CARS-2). 
Additional developmental/cognitive testing, speech and 
language evaluation, and an occupational therapy 
evaluation may be completed to determine additional 
services. It is important to keep in mind that most Applied 
Behavior Analysis (ABA) therapy providers in Iowa ask for  
a standardized test score (e.g., ADOS or CARS-2-ST) to 
enroll in therapy.
SYMPTOM
By 12 months Does not respond to name.
By 14 months
Does not point at objects to  
show interest.
By 18 months Does not pretend play.
General Avoids eye contact and may want  
to be alone.
Has trouble understanding other 
people’s feelings or talking about  
their own feelings.
Has delayed speech and language skills.
Repeats words or phrases over and  
over (echolalia).
Gives unrelated answers to questions.
Gets upset by minor changes.
Has obsessive interests.
Makes repetitive movements like 
flapping hands, rocking, or spinning  
in circles.
Has unusual reactions to the way  
things sound, smell, taste, look, or feel.
AAP recommends screening for autism for all 
children at 18 and 24 months.
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• Mood changes, irritability
• Increased tics
















~8-10 hours Tablet, capsule, 
chewable 
tablet, liquid
Preparations differ in terms of 
immediate release:extended release 
component (30:70, 40:60, 50:50).
All capsules can be opened and 
sprinkled on spoonful of food for 
intake.
Concerta must be swallowed whole. 
Request “authorized generic.”
ODTs should not be chewed.
Jornay PM is taken the night before.  
May interfere with sleep.
Aptensio XR
Concerta










Adzenys XR – ODT
Dexedrine










~24 hours Capsule Must be swallowed whole.  
Cannot be opened and sprinkled.





Tablet Extended release tablets must be 
swallowed whole. Cannot be crushed 
or chewed. Common side effects: 
fatigue, drowsiness, hypotension.  
Do not stop abruptly.
Adapted from https://chadd.org/wp-content/uploads/2019/07/Medication-Chart-July-2019.pdf
*FDA-approved medications only. Please refer to http://www.adhdmedicationguide.com/ for the most up-to-date,  
  detailed medication guide.
Medications for Management of ADHD*




CDC Learn the Signs –  
https://www.cdc.gov/ncbddd/actearly/index.html
Child Mind Institute – https://childmind.org/topics/
disorders/autism-spectrum-disorder/ 
Autism Speaks Toolkits –  
https://www.autismspeaks.org/autism-speaks-tool-kits 
Autism Navigator – https://autismnavigator.com/
ASD Resources 
Early ACCESS Referral – call: 1-888-IAKIDS1(1-888- 
425-4371) or visit: www.iafamilysupportnetwork.org
Iowa Regional Autism Assistance Program – https://
chsciowa.org/regional-autism-assistance-program.asp
CDC Autism Training Modules – https://www.cdc.gov/
ncbddd/actearly/autism/case-modules/index.html
CDC DSM-5 Criteria for ASD -  
https://www.cdc.gov/ncbddd/autism/hcp-dsm.html 
ADHD Resources
Riddle MA. Pediatric Psychopharmacology for Primary Care 
(2nd Ed.) 2019. American Academy of Pediatrics.
Medication Chart with Detailed Dosing Guide –  
www.adhdmedicationguide.com
ADHD Medication Chart – https://chadd.org/wp-content/
uploads/2019/07/Medication-Chart-July-2019.pdf
National Center for ADHD – Extensive resources for 
parents, educators, and professionals at: www.chadd.org
AAP ADHD Guideline – Clinical Practice Guideline for the 
Diagnosis, Evaluation, and Treatment of Attention-Deficit/
Hyperactivity Disorder in Children and Adolescents. 
Pediatrics. October 2019. 144 (4) e20192528. https://
pediatrics.aappublications.org/content/144/4/e20192528
ADHD Toolkit – https://www.aap.org/en-us/pubserv/
adhd2/Pages/kit/data/introframe.html
Understood.org  – https://www.understood.org/
CDC DSM-5 Criteria for ADHD –  
https://www.cdc.gov/ncbddd/adhd/diagnosis.html 
American Psychiatric Association. (2013). Diagnostic  
and Statistical Manual of Mental Disorders (5th ed.). 
Washington, DC.
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Interventions
The goals of management are to: 1. minimize core  
deficits (social communication and restricted,  
repetitive patterns of behavior), 2. maximize functional 
independence by facilitating learning and daily living 
skills, and 3. eliminate or minimize problem behaviors 
that interfere with functioning. 
Therapy 
• Speech and language therapy to address language 
impairments, occupational therapy for fine motor 
delay and activities of daily living, and/or physical 
therapy for gross motor or coordination difficulties  
are recommended.
• Behavior therapy interventions grounded in principles 
of ABA have demonstrated the most effectiveness in 
improving communication and social engagement 
and minimizing behaviors (e.g., aggression). 
• Parental participation and hands-on training is 
strongly recommended for implementation of 
strategies at home and successful skill development.
• Iowa’s Regional Autism Assistance Program has 
family navigators who can help families identify 
and connect to local resources for their child with 
suspected or confirmed autism. Referral can be  
made by a physician. Services are free.
School interventions 
• Children and adolescents with autism may be eligible 
for school services as part of the 504 Rehabilitation 
Act plan (504 plan) or an Individualized Education Plan 
(IEP) under the Individuals with Disabilities Education 
Act (IDEA), based on functional impairment.
• Classroom-based models using principles of ABA in  
an inclusive general education setting are most 
helpful in learning new skills and social interactions. 
• In Iowa, a formal diagnosis of autism is not necessary 
to start services in school.
• In Iowa, the Family & Educator Partnership provides 
an opportunity for parents and educators to build 
partnerships to improve educational programs for 
children with special needs and has a designated 
Family & Educator Coordinator for each AEA.
• Each AEA has a trained challenging behavior team 
that can provide consultative services to teachers to 
improve behavior supports for children with autism.
Medical management of  
co-occurring conditions 
Children with ASD have higher prevalence of GI 
symptoms, constipation, selective eating, obesity,  
sleep problems, developmental delays, motor 
coordination disorders, and behavioral or psychiatric 
conditions. These should be managed individually with 
appropriate therapeutic or medical interventions in the 
primary care office, or in conjunction with a specialist. 
Self-injury or aggression, if present, may require a 
combination of intensive behavior intervention  
and psychopharmacologic agents. 
Families should be asked about complementary, 
integrative, or alternative therapies used at each visit.  
In studies, dietary elimination of gluten- and casein- 
containing foods have not demonstrated improvement in 
core features of autism. Cannabidiol (medical marijuana) 
is approved for use for management of irritability and 
aggression in children with autism in Iowa; there is lack of 
evidence to recommend its widespread use at this time. 
Partnering with families and transition  
to adulthood
It is important for the PCC to provide a medical home 
model with family-centered care for children with ASD. 
Families of children with autism are under chronic stress 
and will need additional support throughout various 
transitions during childhood and adulthood. Autism 
Speaks has developed several toolkits for parents and 
professionals on commonly identified issues. For 
transition to adulthood Got Transition® has a wealth of 
information for families and health care providers related 
to health care, education, employment, guardianship  
and decision making, SSI benefits, and others.  
Please note: article references are on page 6.
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If you have questions about billing related to EPSDT Care for Kids services, please call 
Provider Services:  1- 800-338-7909. If you have questions about clinical issues and 
EPSDT Care for Kids services, please call 1- 800-383-3826. Please note: Due to budget 
restraints, the EPSDT Care for Kids Newsletter is sent to offices and organizations, rather  
than to individuals. The newsletter is also available online at www.iowaepsdt.org. 
Readers are welcome to photocopy or download material from the newsletter to share 
with others. If you wish to reproduce material from the newsletter in another publication, 
whether print or electronic, please obtain permission prior to publication by contacting 
the editor. Please include the following acknowledgment with reprinted material: 
Reprinted by permission of the Iowa EPSDT Care for Kids Newsletter.
The EPSDT Care for Kids Newsletter is published three  
times a year, in print and online, as a joint effort of  
the Iowa Department of Human Services, the Iowa 
Department of Public Health, and the Center for 
Disabilities and Development, which is nationally 
designated as Iowa’s University Center for Excellence  
in Developmental Disabilities. The goal of this newsletter  
is to inform Iowa health care professionals about the 
EPSDT Care for Kids program, to encourage them to  
make use of this important resource, and to provide  
them with information about a wide range of 
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